Security key
55083R203
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (LYEL)
CUSIP: 55083R203
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.0001
- Total 13F shares
- 35
- Total 13F value
- $492
- Share change
- 0
- SEC-reported price per share
- $14.06
- Number of holders
- 1
- Shares outstanding
- 24,390,244
Holder snapshot
3 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
1
Top holders
1
LYEL full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Lyell Immunopharma, Inc. SEC filings
Lyell Immunopharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 55083R203
Recent filing periods:
Ownership snapshot
Top reported holders of LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARCH Venture Fund IX, L.P.
Disclosed value leader
GSK plc
Comparable rows
15/15
Latest evidence
18 May 2026
13D/G
13F
3/4/5
Lead comparable stake: 14%
13D/G row: ARCH Venture Fund IX, L.P.
Showing 1-6 of 15 holder rows.
Quick read
ARCH Venture Fund IX, L.P. leads the comparable SEC ownership view at 14%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARCH Venture Fund IX, L.P.'s linked filing trail.
Comparable ownership
Top 5
ARCH Venture Fund IX, L.P.
14%
Innovative Cellular Therapeutics ...
12%
Foresite Capital Fund IV, L.P.
7.6%
Euler Fund, L.P.
6.7%
Explore Investments LLC/DE
6.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. |
13D/G
|
14%
|
$65,138,070
3,247,162 shares
|
-$669,012,113 | 31 Mar 2026 |
| Innovative Cellular Therapeutics Holdings Ltd |
13D/G
Innovative Cellular Therapeutics Holdings Limited
|
12%
|
$60,180,000
3,000,000 shares
|
+$22,066,000 | 18 May 2026 |
| Foresite Capital Fund IV, L.P. |
13D/G
James B. Tananbaum
|
7.6%
|
$23,622,818
1,454,616 shares
|
$0 | 30 Sep 2025 |
| Euler Fund, L.P. |
13D/G
|
6.7%
|
$43,908,532
1,426,528 shares
|
$0 | 06 Mar 2026 |
| Explore Investments LLC/DE |
13D/G
Explore Investments LLC
|
6.6%
|
$47,064,282
1,529,054 shares
|
+$15,023,410 | 31 Mar 2026 |
| Gates Frontier, LLC |
13D/G
|
5.6%
|
$10,628,242
1,040,964 shares
|
$0 | 25 Jul 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
35
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
72
Q2 2026 holders
1
Holder diff
-71
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend